Table 3.
Changes over time of the variables.
| Variable | 0 Month | 6 Months | 12 Months | 18 Months | 24 Months |
|---|---|---|---|---|---|
| AI group | |||||
| Corrected Ca, mg/dL | 9.6 ± 0.3 | 9.6 ± 0.3 | 9.5 ± 0.3 | 9.6 ± 0.4 | 9.5 ± 0.4 |
| Serum iP, mg/dL | 3.9 ± 0.4 | 3.6 ± 0.4* | 3.5 ± 0.3** | 3.6 ± 0.5** | 3.4 ± 0.4** |
| eGFR, mL/min/1.73 m2 | 81.8 ± 15.2 | 82.5 ± 15.6 | 79.9 ± 16.2 | 78.3 ± 15.4** | 76.1 ± 11.6** |
| Urine Ca/Cr ratio | 0.24 ± 0.19 | – | 0.18 ± 0.10 | – | 0.18 ± 0.11 |
| Intact-PTH, pg/mL | 56.0 ± 23.9 | – | 42.9 ± 17.1 | – | 49.7 ± 19.1** |
| PO group | |||||
| Corrected Ca, mg/dL | 9.3 ± 0.4 | 9.3 ± 0.4 | 9.4 ± 0.4 | 9.6 ± 0.4 | 9.5 ± 0.4 |
| Serum iP, mg/dL | 3.6 ± 0.5 | 3.8 ± 0.5 | 3.5 ± 0.4 | 3.5 ± 0.4 | 3.5 ± 0.4 |
| eGFR, mL/min/1.73 m2 | 72.6 ± 21.0 | 70.0 ± 16.4 | 68.2 ± 13.9* | 64.9 ± 12.1** | 63.4 ± 12.5** |
| Urine Ca/Cr ratio | 0.23 ± 0.15 | – | 0.29 ± 0.15* | – | 0.27 ± 0.14 |
| Intact-PTH, pg/mL | 35.8 ± 14.6 | – | 33.8 ± 18.5 | – | 31.2 ± 15.9** |
Values are presented as mean ± standard deviation.
AI group, therapy of aromatase inhibitor-induced osteoporosis; PO group, patients of primary postmenopausal osteoporosis.
Corrected Ca, serum-corrected calcium; serum iP, serum phosphate; eGFR, estimated glomerular filtration rate; Cr, creatinine; PTH, parathyroid hormone.
Wilcoxon signed-rank test.
*P < 0.05. **P < 0.01.